Tag: ARneg

Androgen receptor negative: Cells that do not have a nuclear receptor protein that binds androgenic hormones such as testosterone and dihydrotestosterone. In other words, AR- cells lack an interior receptor that is activated by androgens.

Studies

  • The androgen receptor is a tumor suppressor in estrogen receptor–positive breast cancer Cite
    Hickey TE, Selth LA, Chia KM, Laven-Law G, Milioli HH, Roden D, et al. The androgen receptor is a tumor suppressor in estrogen receptor–positive breast cancer. Nature Medicine. Springer Science and Business Media LLC; 2021; 10.1038/s41591-020-01168-7
  • Role of androgen receptor expression in early stage ER+/PgR−/HER2– breast cancer Cite
    Tagliaferri B, Quaquarini E, Palumbo R, Balletti E, Presti D, Malovini A, et al. Role of androgen receptor expression in early stage ER+/PgR−/HER2– breast cancer. Therapeutic Advances in Medical Oncology. SAGE Publications; 2020; 12:175883592095835 10.1177/1758835920958355
  • Triple-negative pleomorphic lobular carcinoma and expression of androgen receptor: Personal case series and review of the literature Cite
    Taniguchi K, Takada S, Omori M, Igawa T, Nishimura MF, Morito T, et al. Triple-negative pleomorphic lobular carcinoma and expression of androgen receptor: Personal case series and review of the literature. PLOS ONE. Public Library of Science (PLoS); 2020; 15:e0235790 10.1371/journal.pone.0235790
  • Abstract B105: The impact of ancestry on mutational and immune signatures in triple-negative breast cancers Cite
    Hughley RW, Yates C, Polak P. Abstract B105: The impact of ancestry on mutational and immune signatures in triple-negative breast cancers. Poster Presentations - Proffered Abstracts. American Association for Cancer Research; 2020; 10.1158/1538-7755.disp19-b105
  • Biological and clinical features of early triple-negative invasive lobular carcinomas of the breast. Cite
    Conforti F, Pala L, Guerini Rocco E, Pagan E, Bagnardi V, Montagna E, et al. Biological and clinical features of early triple-negative invasive lobular carcinomas of the breast.. Journal of Clinical Oncology. American Society of Clinical Oncology (ASCO); 2020; 38:e12570-e12570 10.1200/jco.2020.38.15_suppl.e12570
  • Gene expression profiles for low-dose exposure to diethyl phthalate in rodents and humans: a translational study with implications for breast carcinogenesis Cite
    Gopalakrishnan K, Aushev VN, Manservisi F, Falcioni L, Panzacchi S, Belpoggi F, et al. Gene expression profiles for low-dose exposure to diethyl phthalate in rodents and humans: a translational study with implications for breast carcinogenesis. Scientific Reports. Springer Science and Business Media LLC; 2020; 10 10.1038/s41598-020-63904-w
  • Quadruple negative breast cancer Cite
    Huang M, Wu J, Ling R, Li N. Quadruple negative breast cancer. Breast Cancer. Springer Science and Business Media LLC; 2020; 27:527-533 10.1007/s12282-020-01047-6
  • Tumor characteristics and outcome by androgen receptor expression in triple-negative breast cancer patients treated with neo-adjuvant chemotherapy Cite
    Jongen L, Floris G, Wildiers H, Claessens F, Richard F, Laenen A, et al. Tumor characteristics and outcome by androgen receptor expression in triple-negative breast cancer patients treated with neo-adjuvant chemotherapy. Breast Cancer Research and Treatment. Springer Science and Business Media LLC; 2019; 176:699-708 10.1007/s10549-019-05252-6
  • Androgen Receptor Expression and Breast Cancer Survival: Results From the Nurses’ Health Studies Cite
    Kensler KH, Poole EM, Heng YJ, Collins LC, Glass B, Beck AH, et al. Androgen Receptor Expression and Breast Cancer Survival: Results From the Nurses’ Health Studies. JNCI: Journal of the National Cancer Institute. Oxford University Press (OUP); 2018; 111:700-708 10.1093/jnci/djy173
  • Androgen receptor in advanced breast cancer: is it useful to predict the efficacy of anti-estrogen therapy? Cite
    Bronte G, Rocca A, Ravaioli S, Puccetti M, Tumedei MM, Scarpi E, et al. Androgen receptor in advanced breast cancer: is it useful to predict the efficacy of anti-estrogen therapy?. BMC Cancer. Springer Science and Business Media LLC; 2018; 18 10.1186/s12885-018-4239-3
  • The Magnitude of Androgen Receptor Positivity in Breast Cancer Is Critical for Reliable Prediction of Disease Outcome Cite
    Ricciardelli C, Bianco-Miotto T, Jindal S, Butler LM, Leung S, McNeil CM, et al. The Magnitude of Androgen Receptor Positivity in Breast Cancer Is Critical for Reliable Prediction of Disease Outcome. Clinical Cancer Research. American Association for Cancer Research (AACR); 2018; 24:2328-2341 10.1158/1078-0432.ccr-17-1199
  • The Androgen Receptor Supports Tumor Progression After the Loss of Ovarian Function in a Preclinical Model of Obesity and Breast Cancer Cite
    Wellberg EA, Checkley LA, Giles ED, Johnson SJ, Oljira R, Wahdan-Alaswad R, et al. The Androgen Receptor Supports Tumor Progression After the Loss of Ovarian Function in a Preclinical Model of Obesity and Breast Cancer. Hormones and Cancer. Springer Science and Business Media LLC; 2017; 8:269-285 10.1007/s12672-017-0302-9
  • Abstract 4826: Maternal high butter fat intake heightens mammary cancer risk in offsprings gestationally exposed to bisphenol A at environmentally relevant dose Cite
    Leung Y, Govindarajah V, Cheong A, Song D, Zhu X, Ying J, et al. Abstract 4826: Maternal high butter fat intake heightens mammary cancer risk in offsprings gestationally exposed to bisphenol A at environmentally relevant dose. Tumor Biology. American Association for Cancer Research; 2017; 10.1158/1538-7445.am2017-4826
  • Beyond triple-negative breast cancer and African ancestry: Tumor phenotypes among internationally diverse patient populations. Cite
    Jiagge EM, Jibril A, Divine G, Gyan KK, Bensenhaver JM, Oppong JK, et al. Beyond triple-negative breast cancer and African ancestry: Tumor phenotypes among internationally diverse patient populations.. Journal of Clinical Oncology. American Society of Clinical Oncology (ASCO); 2017; 35:1101-1101 10.1200/jco.2017.35.15_suppl.1101
  • Androgen Receptor Supports an Anchorage-Independent, Cancer Stem Cell-like Population in Triple-Negative Breast Cancer Cite
    Barton VN, Christenson JL, Gordon MA, Greene LI, Rogers TJ, Butterfield K, et al. Androgen Receptor Supports an Anchorage-Independent, Cancer Stem Cell-like Population in Triple-Negative Breast Cancer. Cancer Research. American Association for Cancer Research (AACR); 2017; 77:3455-3466 10.1158/0008-5472.can-16-3240
  • A comparison of the molecular subtypes of triple-negative breast cancer among non-Asian and Taiwanese women Cite
    Tseng L, Chiu J, Liu C, Tsai Y, Wang Y, Yang C, et al. A comparison of the molecular subtypes of triple-negative breast cancer among non-Asian and Taiwanese women. Breast Cancer Research and Treatment. Springer Science and Business Media LLC; 2017; 163:241-254 10.1007/s10549-017-4195-7
  • Abstract B20: Targeting androgen receptor and vitamin D receptor in triple negative breast cancers Cite
    Thakkar A, Wang B, Picon-Ruiz M, Ince T. Abstract B20: Targeting androgen receptor and vitamin D receptor in triple negative breast cancers. Targeting Epigenetics. American Association for Cancer Research; 2017; 10.1158/1557-3265.pmccavuln16-b20
  • Special considerations in the evaluation and management of breast cancer in men11This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors. Cite
    Massarweh SA, Choi GL. Special considerations in the evaluation and management of breast cancer in men11This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.. Current Problems in Cancer. Elsevier BV; 2016; 40:163-171 10.1016/j.currproblcancer.2016.09.003
  • Antiproliferative Effect of Androgen Receptor Inhibition in Mesenchymal Stem-Like Triple-Negative Breast Cancer Cite
    Zhu A, Li Y, Song W, Xu Y, Yang F, Zhang W, et al. Antiproliferative Effect of Androgen Receptor Inhibition in Mesenchymal Stem-Like Triple-Negative Breast Cancer. Cellular Physiology and Biochemistry. S. Karger AG; 2016; 38:1003-1014 10.1159/000443052
  • Differential Effects of Organic and Inorganic Mercury on Phenotypically Variant Breast Cancer Cell Lines Cite
    R Wallace D. Differential Effects of Organic and Inorganic Mercury on Phenotypically Variant Breast Cancer Cell Lines. Journal of Clinical Toxicology. OMICS Publishing Group; 2016; 05 10.4172/2161-0495.1000273
  • Clinical verification of sensitivity to preoperative chemotherapy in cases of androgen receptor-expressing positive breast cancer Cite
    Asano Y, Kashiwagi S, Onoda N, Kurata K, Morisaki T, Noda S, et al. Clinical verification of sensitivity to preoperative chemotherapy in cases of androgen receptor-expressing positive breast cancer. British Journal of Cancer. Springer Science and Business Media LLC; 2016; 114:14-20 10.1038/bjc.2015.434
  • Androgen receptor and antiandrogen therapy in male breast cancer Cite
    Di Lauro L, Barba M, Pizzuti L, Vici P, Sergi D, Di Benedetto A, et al. Androgen receptor and antiandrogen therapy in male breast cancer. Cancer Letters. Elsevier BV; 2015; 368:20-25 10.1016/j.canlet.2015.07.040
  • Role of Androgen and Estrogen Receptors as Prognostic and Potential Predictive Markers of Ductal Carcinoma in Situ of the Breast Cite
    Tumedei MM, Silvestrini R, Ravaioli S, Massa I, Maltoni R, Rocca A, et al. Role of Androgen and Estrogen Receptors as Prognostic and Potential Predictive Markers of Ductal Carcinoma in Situ of the Breast. The International Journal of Biological Markers. SAGE Publications; 2015; 30:425-428 10.5301/jbm.5000163
  • Age at first childbirth and oral contraceptive use are associated with risk of androgen receptor-negative breast cancer: the Malmö Diet and Cancer Cohort Cite
    Elebro K, Butt S, Dorkhan M, Jernström H, Borgquist S. Age at first childbirth and oral contraceptive use are associated with risk of androgen receptor-negative breast cancer: the Malmö Diet and Cancer Cohort. Cancer Causes & Control. Springer Science and Business Media LLC; 2014; 25:945-957 10.1007/s10552-014-0394-2
  • Androgen Receptor Expression and Outcomes in Early Breast Cancer: A Systematic Review and Meta-Analysis Cite
    Vera-Badillo FE, Templeton AJ, de Gouveia P, Diaz-Padilla I, Bedard PL, Al-Mubarak M, et al. Androgen Receptor Expression and Outcomes in Early Breast Cancer: A Systematic Review and Meta-Analysis. JNCI Journal of the National Cancer Institute. Oxford University Press (OUP); 2013; 106:djt319-djt319 10.1093/jnci/djt319
  • Comparative study on transcriptional activity of 17 parabens mediated by estrogen receptor α and β and androgen receptor Cite
    Watanabe Y, Kojima H, Takeuchi S, Uramaru N, Ohta S, Kitamura S. Comparative study on transcriptional activity of 17 parabens mediated by estrogen receptor α and β and androgen receptor. Food and Chemical Toxicology. Elsevier BV; 2013; 57:227-234 10.1016/j.fct.2013.03.036
  • Endocrine Disruptors Fludioxonil and Fenhexamid Stimulate miR-21 Expression in Breast Cancer Cells Cite
    Teng Y, Manavalan TT, Hu C, Medjakovic S, Jungbauer A, Klinge CM. Endocrine Disruptors Fludioxonil and Fenhexamid Stimulate miR-21 Expression in Breast Cancer Cells. Toxicological Sciences. Oxford University Press (OUP); 2012; 131:71-83 10.1093/toxsci/kfs290
  • Estrogenic and androgenic activities in total plasma measured with reporter-gene bioassays: Relevant exposure measures for endocrine disruptors in epidemiologic studies? Cite
    Brouwers MM, Besselink H, Bretveld RW, Anzion R, Scheepers PT, Brouwer A, et al. Estrogenic and androgenic activities in total plasma measured with reporter-gene bioassays: Relevant exposure measures for endocrine disruptors in epidemiologic studies?. Environment International. Elsevier BV; 2011; 37:557-564 10.1016/j.envint.2010.11.001